For the third quarter of the fiscal year ending March 2026, net sales amounted to \u00a554,486 million (9.1% Year-over-Year increase), operating income was \u00a54,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was \u00a53,904 million (4.7% Year-over-Year decrease).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4886-20260202-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales amounted to \u00a554,486 million (9.1% Year-over-Year increase), operating income was \u00a54,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was \u00a53,904 million (4.7% Year-over-Year decrease).","jir_summary":"### Overview of Performance\nDuring the consolidated cumulative third quarter of the fiscal year ending March 2026, net sales reached \u00a554,486 million (9.1% increase Year-over-Year), driven by steady performance in the pharmaceutical and animal health businesses as well as increased contributions from overseas operations. Conversely, operating income was \u00a54,911 million (10.6% decrease Year-over-Year), ordinary income was \u00a54,854 million (10.9% decrease Year-over-Year), and net income attributable to owners of the parent was \u00a53,904 million (4.7% decrease Year-over-Year). The primary cause of the profit decline was increased selling, general and administrative expenses, including higher research and development costs.\n\n### Segment Performance\nThe pharmaceutical business recorded net sales of \u00a545,332 million (2.9% increase Year-over-Year), with core products \"Lelmina,\" \"Droeth,\" \"Thyradin,\" and \"Rifixima\" showing sales growth; however, segment profit was \u00a55,822 million (6.1% decrease Year-over-Year). The animal health business achieved net sales of \u00a55,759 million (1.0% increase Year-over-Year) and segment profit of \u00a5368 million (22.6% increase Year-over-Year). The overseas business, which newly consolidated a Vietnamese subsidiary, posted net sales of \u00a53,240 million and segment profit of \u00a570 million. Other businesses recorded net sales of \u00a5153 million (7.7% decrease Year-over-Year) and a loss of \u00a528 million.\n\n### Financial Position and Outlook\nTotal assets amounted to \u00a5112,699 million (an increase of \u00a58,404 million from the end of the previous fiscal year), liabilities were \u00a537,956 million (increase of \u00a55,475 million), and net assets stood at \u00a574,743 million (increase of \u00a52,928 million). The equity ratio was 61.0%, down 1.6 points from the previous fiscal year-end. There is no change to the consolidated earnings forecast for the fiscal year ending March 2026, with expected net sales of \u00a571,000 million, operating income of \u00a56,000 million, and net income attributable to owners of the parent of \u00a55,000 million.","jir_financial_highlights":"Net Sales: \u00a554,486 million (9.1% Year-over-Year increase)\nOperating Income: \u00a54,911 million (10.6% Year-over-Year decrease)\nOrdinary Income: \u00a54,854 million (10.9% Year-over-Year decrease)\nNet Income Attributable to Owners of Parent: \u00a53,904 million (4.7% Year-over-Year decrease)\nTotal Assets: \u00a5112,699 million (Increase of \u00a58,404 million from previous fiscal year-end)\nNet Assets: \u00a574,743 million (Increase of \u00a52,928 million from previous fiscal year-end)\nEquity Ratio: 61.0% (Declined by 1.6 points from previous fiscal year-end)\nTotal R&D Expenses: \u00a55,405 million (Unknown)\nNumber of Shares Outstanding (Including Treasury Stock): 28,763,199 shares (Same as previous period)\nTreasury Stock at Period End: 367,074 shares (Decreased compared to previous period (399,476 shares \u2192 367,074 shares))","jir_category":"","jir_hashtags":"#AsukaPharmaceuticalHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a554,486 million (9.1% Year-over-Year increase)\nOperating Income: \u00a54,911 million (10.6% Year-over-Year decrease)\nNet Income Attributable to Owners of Parent: \u00a53,904 million (4.7% Year-over-Year decrease)","jir_meta_title":"Asuka Pharmaceutical Holdings Q3 Fiscal 2026 Financial Summary: 9.1% Sales Growth Amid Profit Decrease","jir_meta_description":"Asuka Pharmaceutical Holdings' Q3 financial summary for fiscal year ending March 2026. Net sales reached \u00a554,486 million (9.1% YoY growth), operating income was \u00a54,911 million (10.6% YoY decline), and net income was \u00a53,904 million (4.7% YoY decline). Pharmaceutical and overseas businesses contributed to revenue growth.","jir_og_title":"Asuka Pharmaceutical Holdings Q3 Fiscal 2026 Earnings Announcement","jir_og_description":"Net sales increased 9.1% Year-over-Year to \u00a554,486 million, while profits declined. Detailed report on pharmaceutical and overseas business trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[49926,54486],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[5495,4911],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[4098,3904],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"FY2026 Q3 Revenue Breakdown by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Animal Health Business\\\",\\\"Overseas Business\\\",\\\"Other Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[45332,5759,3240,153],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]}}\"}, {\"jir_chart_id\": \"segment_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2026 Q3 Segment Profit (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Animal Health Business\\\",\\\"Overseas Business\\\",\\\"Other Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Segment Profit\\\",\\\"data\\\":[5822,368,70,-28],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-23070","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n